NatImmune A/S has developed a product for replacement therapy of Mannan Binding Lectin (MBL) in patients carrying genetic pre-disposition to infections through a deficiency in the immune system. The project is partnered with ENZON Pharmaceuticals, Inc.
Missing: NatImmune's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: NatImmune's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
NatImmune Frequently Asked Questions (FAQ)
What is NatImmune's latest funding round?
NatImmune's latest funding round is Other Investors.
Who are the investors of NatImmune?
Investors of NatImmune include Novo Holdings.
Who are NatImmune's competitors?
Competitors of NatImmune include AVEO Oncology, ISA Pharmaceuticals, Syndax Pharmaceuticals, Salix Pharmaceuticals, Nps Pharmaceuticals and 11 more.
Compare NatImmune to Competitors
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Psimei Pharmaceuticals is developing boron-based drugs for applications in Photon Activation Therapy (PAT). This involves the use of standard radiotherapy to activate boron-based compounds which selectively target solid tumours. This results in an amplification of the therapeutic effect of conventional radiotherapy. Pre-clinical data for Psimei's lead product, PP200PAT, has demonstrated 90% true cure rates at 6 months in tumour models compared with 30% for conventional radiotherapy alone. It also enabled much shorter treatment regimes - days as opposed to weeks. This drug is being prepared for clinical development.
The company are a technology development and licensing firm with a strong focus on robotics and machine intelligence applications and their integration into industries such as pharmaceuticals and health care. The company take great pride in the company's diverse and knowledgeable staff, who make such ventures possible. Wrightwood Technologies Inc. aims to provide both the public and private sectors with technologies and services that improve efficiency, increase production, reduce costs, eliminate waste, and improve societies' over-all quality of life.
Arriva Pharmaceuticals, Inc. offers enzyme inhibitor replacement & therapy
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Oxyrane is a biopharmaceutical company dedicated to the development of biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.